Omeros Corp (OMER) 16.25 $OMER
Hepatocellular Carcinoma - Pipeline Review, H1 2015
M2 - Wed Aug 26, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xkv4n3/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 100 companies featured in this report: - 4SC AG - Acceleron Pharma - Bayer - Bio-Cancer Treatment International - Caladrius Biosciences - Can-Fite BioPharma - Delcath Systems - Dicerna Pharmaceuticals - Eisai - F. Hoffmann-La Roche - Gamida Cell - Immune Network - Immunicum - Johnson & Johnson - KAHR medical - Ligand Pharmaceuticals, - Lixte Biotechnology Holdings - MaxCyte - Nerviano Medical Sciences - Nimbus Therapeutics - Omeros Corporation - Panacea Pharmaceuticals - Raptor Pharmaceuticals - Shenogen Pharma - Taiwan Liposome - VasGene Therapeutics For more information visit http://www.researchandmarkets.com/research/xk...tocellular
CANF: 1.68 (-0.04), JNJ: 95.11 (+4.38), RPTP: 12.47 (+0.59), DRNA: 10.52 (+0.44), DCTH: 0.40 (-0.04), CLBS: 1.27 (-0.01), OMER: 16.25 (-0.32), XLRN: 28.25 (+1.25)
The Zacks Analyst Blog Highlights: Omeros, AbbVie, Kite Pharma and Avalanche
Zacks Equity Research - Zacks Investment Research - Thu Aug 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Omeros, AbbVie, Kite Pharma and Avalanche
KITE: 51.53 (+1.49), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)
Spinal Cord Injury - Pipeline Review, H1 2015
M2 - Thu Aug 20, 6:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfj5g3/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Cord Injury and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Acorda Therapeutics - Asubio Pharma - Athersys - Axerion Therapeutics - BioArctic Neuroscience - Faron Pharmaceuticals - FirstString Research - Genervon Biopharmaceuticals - Grupo Ferrer Internaciona - Hemostemix - Histocell - Intellipharmaceutics International - K-Stemcell - Kadimastem - Kringle Pharma - Lipopharma Therapeutics - Lpath - MandalMed - Mapreg - Mitsubishi Tanabe Pharma Corporation - Neuralstem - Neuronax - Omeros Corporation - PharmatrophiX - Pharmicell - Q Therapeutics - Quark Pharmaceuticals - Remedy Pharmaceuticals - RhinoCyte - SanBio - Sirnaomics - StemCells - Stemedica Cell Technologies - TissueGene - Vertex Pharmaceuticals Incorporated - Vicore Pharma For more information visit http://www.researchandmarkets.com/research/pf...pinal_cord
VRTX: 130.11 (+8.94), IPCI: 2.10 (+0.03), ACOR: 31.96 (+0.59), OMER: 16.25 (-0.32)
Omeros' Reveals Positive Data on OMS721 from Phase II
Zacks Equity Research - Zacks Investment Research - Wed Aug 19, 3:55PM CDT
Omeros Corporation (OMER) announced positive data from the second cohort and data-to-date from the third cohort of an ongoing phase II study on OMS721.
VRX: 227.24 (+7.16), ALXN: 173.54 (+8.10), HSP: 89.84 (+0.01), OMER: 16.25 (-0.32)
Critical Alerts For Chesapeake Energy, Omeros, Second Sight Medical Products Inc., Denbury Resources and Whiting Petroleum Released By InvestorsObserver
PR Newswire - Wed Aug 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CHK, OMER, EYES, DNR and WLL.
EYES: 9.14 (+0.32), WLL: 14.70 (-0.02), CHK: 6.34 (+0.31), DNR: 3.43 (+0.15), OMER: 16.25 (-0.32)
Parkinson's Disease - Pipeline Review, H1 2015
M2 - Wed Aug 19, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3dnpc/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AbbVie - AC Immune - Bial - Portela & Ca. - Bio-Modeling Systems - CalAsia Pharmaceuticals. - Calico - D-Pharm - Eli Lilly and Company - Euroscreen - F. Hoffmann-La Roche - Gene Solutions - Genecode - Harbor Therapeutics - Intec Pharma. - Jeil Pharmaceutical - KineMed - Lead Discovery Center - Ligand Pharmaceuticals - Medeia Therapeutics - MedGenesis Therapeutix . - Neuralstem - Omeros Corporation - Oncodesign - P2D Bioscience - Peptron - QR Pharma - Raptor Pharmaceuticals - Reata Pharmaceuticals - SanBio - Saneron CCEL Therapeutics - Takeda Pharmaceutical - UCB - Upsher-Smith Laboratories - Varinel - Zenobia Therapeutics For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/l3dnpc/parkinsons
NTEC: 5.75 (-0.04), RPTP: 12.47 (+0.59), LLY: 81.10 (+2.84), OMER: 16.25 (-0.32)
Omeros (OMER) Catches Eye: Stock Adds 72% in Session
Zacks Equity Research - Zacks Investment Research - Wed Aug 19, 7:51AM CDT
Omeros Corporation (OMER) was a big mover last session, as its shares rose roughly 72% on the day.
ABAX: 46.96 (+0.56), OMER: 16.25 (-0.32)
Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Arpita Dutt - Zacks Investment Research - Wed Aug 19, 7:33AM CDT
Kite Pharma (KITE) provided an update on KTE-C19 and remains on track to provide data later this year at ASH.
BIIB: 298.25 (+16.51), KITE: 51.53 (+1.49), AMGN: 153.98 (+8.79), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)
Omeros (OMER) Stock Spikes on Positive Phase 2 Test Data
at The Street - Tue Aug 18, 10:18AM CDT
Omeros (OMER) shares are up over 70% on Tuesday after the company revealed more positive phase 2 test results of its thrombotic microangiopathies treatment candidate.
OMER: 16.25 (-0.32)
Why Omeros Corporation's Stock Rocketed Higher Today
George Budwell, The Motley Fool - Motley Fool - Tue Aug 18, 10:10AM CDT
What : Shares of Omeros Corporation , a biophama company developing small-molecule and protein therapeutics for inflammatory diseases and bleeding and nervous disorders, saw its shares climb by as much as 85% today on tremendous volume. This huge...
OMER: 16.25 (-0.32)
Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
PR Newswire - Tue Aug 18, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) - aggregations of platelets - in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of TMAs, including atypical hemolytic uremic syndrome (aHUS).
OMER: 16.25 (-0.32)
Omeros Announces Plan to File Infringement Suit Against ANDA Filer
PR Newswire - Mon Aug 17, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (Par) in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria® (phenylephrine and ketorolac injection) 1%/0.3%. Omidria is approved by the U.S. Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. As reported in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2015, Omeros received a notice from Par on July 27, 2015, which addresses the ANDA and Par's request to market a generic version of Omidria pursuant to Paragraph IV of the Hatch-Waxman Act following expiration of the drug's New Product Exclusivity and, if applicable, the subsequent Pediatric Exclusivity, but prior to the expiration of three patents published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, which have terms extending to as late as 2033. Approximately 3.8 million cataract and lens replacement procedures are projected in the U.S. in 2015.
OMER: 16.25 (-0.32)
Melanoma - Pipeline Review, H1 2015
M2 - Fri Aug 14, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sfh3j3/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Partial list of the 200 companied featured in this comprehensive report: - Aeterna Zentaris - Altor BioScience - Bayer AG - Bio-Cancer Treatment International - Boston Biomedical - Celgene Corporation - Champions Oncology - DNA Therapeutics - DormaTarg - EcoBiotics - Eli Lilly and Company - F. Hoffmann-La Roche - Galapagos - Hadasit Medical Research Services & Development - KAEL-GemVax - Life Science Pharmaceuticals - MedImmune - Merck & Co. - Millennium Pharmaceuticals - Navigen Pharmaceuticals - Nektar Therapeutics - Omeros Corporation - Pacific Northwest Biotechnology - Pfizer - Pivotal BioSciences - Qu Biologics - Reata Pharmaceuticals - Scancell - Takeda Pharmaceutical Company - Ultimovacs - Vaccibody - Viralytics - Welichem Biotech - ZIOPHARM Oncology For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/sfh3j3/melanoma
ZIOP: 8.40 (+0.37), MRK: 54.42 (+3.25), LLY: 81.10 (+2.84), NKTR: 10.08 (+0.25), OMER: 16.25 (-0.32), CELGZ: 1.68 (+0.12)
BUYINS.NET: SHOR, HAP, DZK, OMER, SCHC, NXPI Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Aug 12, 6:59AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Shoretel Inc (NASDAQ:SHOR), Market Vectors RVE Hard Assets Producers ETF (NYSE:HAP), Direxion Daily Developed Markets Bull 3X Shares (NYSE
ZK), Omeros Corp (NASDAQ:OMER), Schwab US Large Cap Etf (NYSE:SCHC), NXP Semiconductors NV (NASDAQ:NXPI) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
DZK: 53.32 (+3.45), SCHC: 28.93 (+0.74), NXPI: 85.02 (+4.18), HAP: 27.79 (+0.25), OMER: 16.25 (-0.32), SHOR: 7.41 (+0.40)
Omeros reports 2Q loss
Automated Insights - Mon Aug 10, 5:33PM CDT
SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $16.7 million in its second quarter.
OMER: 16.25 (-0.32)
Omeros Corporation Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 10, 3:11PM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the second quarter of 2015, which include:
OMER: 16.25 (-0.32)
Omeros to Present at the 2015 Wedbush PacGrow Healthcare Conference
PR Newswire - Fri Aug 07, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2015 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, August 11 at 12:45 pm EDT.
OMER: 16.25 (-0.32)
Omidria® Approved for Commercialization Throughout the European Union and Additional Countries
PR Newswire - Mon Aug 03, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. This approval allows for the marketing of Omidria in all EU member states plus Iceland, Lichtenstein, and Norway. Cataract surgery and lens replacement are among the most common surgical procedures worldwide, with approximately 3.9 million of them expected to be performed in Western Europe alone in 2015.
OMER: 16.25 (-0.32)
Omeros Corporation to Announce Second Quarter 2015 Financial Results on August 10, 2015
PR Newswire - Fri Jul 31, 3:50PM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its second quarter 2015 financial results for the period ended June 30, 2015, on Monday, August 10, 2015, after market close. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.
OMER: 16.25 (-0.32)
Ischemia Reperfusion Injury Pipeline Review, H1 2015 - 24 Companies & 63 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mw2sb6/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adienne Pharma & Biotech - Alligator Bioscience AB - Antipodean Pharmaceuticals, Inc. - BioLineRx, Ltd. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Catalyst Biosciences, Inc. - Curatis Pharma GmbH - Gilead Sciences, Inc. - Ischemix - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Mercury Pharmaceuticals, Inc. - Omeros Corporation - Opsona Therapeutics Ltd. - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. - Prothix BV - Trophos SA - Zealand Pharma A/S - Zyrnat Biotherapeutics SL Drug Profiles - ADC-1004 - AM/AMBP-1 - ANV-6L15 - APP-103 - BBT-030 - BBT-045 - BL-7060 - C1 esterase inhibitor (recombinant) - CB-2782 - CMX-2043 - CRX-526 - Curaglutide - danegaptide - Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Elafin - EP-80317 - Ergidina - GS-459679 - KN-93 - KR-62980 - LSNTU-106 - mangafodipir - MFH-244 - MG-53 - mirococept - MitoQ - Monoclonal Antibody for Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - MTP-131 - NBD Peptide - NecX - Neutrolide - NOXD-21 For more information visit http://www.researchandmarkets.com/research/mw2sb6/ischemia
GILD: 106.96 (+4.40), OMER: 16.25 (-0.32)
Hepatocellular Carcinoma - Pipeline Review, H1 2015
M2 - Wed Aug 26, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xkv4n3/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 100 companies featured in this report: - 4SC AG - Acceleron Pharma - Bayer - Bio-Cancer Treatment International - Caladrius Biosciences - Can-Fite BioPharma - Delcath Systems - Dicerna Pharmaceuticals - Eisai - F. Hoffmann-La Roche - Gamida Cell - Immune Network - Immunicum - Johnson & Johnson - KAHR medical - Ligand Pharmaceuticals, - Lixte Biotechnology Holdings - MaxCyte - Nerviano Medical Sciences - Nimbus Therapeutics - Omeros Corporation - Panacea Pharmaceuticals - Raptor Pharmaceuticals - Shenogen Pharma - Taiwan Liposome - VasGene Therapeutics For more information visit http://www.researchandmarkets.com/research/xk...tocellular
CANF: 1.68 (-0.04), JNJ: 95.11 (+4.38), RPTP: 12.47 (+0.59), DRNA: 10.52 (+0.44), DCTH: 0.40 (-0.04), CLBS: 1.27 (-0.01), OMER: 16.25 (-0.32), XLRN: 28.25 (+1.25)
The Zacks Analyst Blog Highlights: Omeros, AbbVie, Kite Pharma and Avalanche
Zacks Equity Research - Zacks Investment Research - Thu Aug 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Omeros, AbbVie, Kite Pharma and Avalanche
KITE: 51.53 (+1.49), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)
Spinal Cord Injury - Pipeline Review, H1 2015
M2 - Thu Aug 20, 6:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfj5g3/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Cord Injury and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Acorda Therapeutics - Asubio Pharma - Athersys - Axerion Therapeutics - BioArctic Neuroscience - Faron Pharmaceuticals - FirstString Research - Genervon Biopharmaceuticals - Grupo Ferrer Internaciona - Hemostemix - Histocell - Intellipharmaceutics International - K-Stemcell - Kadimastem - Kringle Pharma - Lipopharma Therapeutics - Lpath - MandalMed - Mapreg - Mitsubishi Tanabe Pharma Corporation - Neuralstem - Neuronax - Omeros Corporation - PharmatrophiX - Pharmicell - Q Therapeutics - Quark Pharmaceuticals - Remedy Pharmaceuticals - RhinoCyte - SanBio - Sirnaomics - StemCells - Stemedica Cell Technologies - TissueGene - Vertex Pharmaceuticals Incorporated - Vicore Pharma For more information visit http://www.researchandmarkets.com/research/pf...pinal_cord
VRTX: 130.11 (+8.94), IPCI: 2.10 (+0.03), ACOR: 31.96 (+0.59), OMER: 16.25 (-0.32)
Omeros' Reveals Positive Data on OMS721 from Phase II
Zacks Equity Research - Zacks Investment Research - Wed Aug 19, 3:55PM CDT
Omeros Corporation (OMER) announced positive data from the second cohort and data-to-date from the third cohort of an ongoing phase II study on OMS721.
VRX: 227.24 (+7.16), ALXN: 173.54 (+8.10), HSP: 89.84 (+0.01), OMER: 16.25 (-0.32)
Critical Alerts For Chesapeake Energy, Omeros, Second Sight Medical Products Inc., Denbury Resources and Whiting Petroleum Released By InvestorsObserver
PR Newswire - Wed Aug 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CHK, OMER, EYES, DNR and WLL.
EYES: 9.14 (+0.32), WLL: 14.70 (-0.02), CHK: 6.34 (+0.31), DNR: 3.43 (+0.15), OMER: 16.25 (-0.32)
Parkinson's Disease - Pipeline Review, H1 2015
M2 - Wed Aug 19, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3dnpc/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AbbVie - AC Immune - Bial - Portela & Ca. - Bio-Modeling Systems - CalAsia Pharmaceuticals. - Calico - D-Pharm - Eli Lilly and Company - Euroscreen - F. Hoffmann-La Roche - Gene Solutions - Genecode - Harbor Therapeutics - Intec Pharma. - Jeil Pharmaceutical - KineMed - Lead Discovery Center - Ligand Pharmaceuticals - Medeia Therapeutics - MedGenesis Therapeutix . - Neuralstem - Omeros Corporation - Oncodesign - P2D Bioscience - Peptron - QR Pharma - Raptor Pharmaceuticals - Reata Pharmaceuticals - SanBio - Saneron CCEL Therapeutics - Takeda Pharmaceutical - UCB - Upsher-Smith Laboratories - Varinel - Zenobia Therapeutics For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/l3dnpc/parkinsons
NTEC: 5.75 (-0.04), RPTP: 12.47 (+0.59), LLY: 81.10 (+2.84), OMER: 16.25 (-0.32)
Omeros (OMER) Catches Eye: Stock Adds 72% in Session
Zacks Equity Research - Zacks Investment Research - Wed Aug 19, 7:51AM CDT
Omeros Corporation (OMER) was a big mover last session, as its shares rose roughly 72% on the day.
ABAX: 46.96 (+0.56), OMER: 16.25 (-0.32)
Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Arpita Dutt - Zacks Investment Research - Wed Aug 19, 7:33AM CDT
Kite Pharma (KITE) provided an update on KTE-C19 and remains on track to provide data later this year at ASH.
BIIB: 298.25 (+16.51), KITE: 51.53 (+1.49), AMGN: 153.98 (+8.79), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)
Omeros (OMER) Stock Spikes on Positive Phase 2 Test Data
at The Street - Tue Aug 18, 10:18AM CDT
Omeros (OMER) shares are up over 70% on Tuesday after the company revealed more positive phase 2 test results of its thrombotic microangiopathies treatment candidate.
OMER: 16.25 (-0.32)
Why Omeros Corporation's Stock Rocketed Higher Today
George Budwell, The Motley Fool - Motley Fool - Tue Aug 18, 10:10AM CDT
What : Shares of Omeros Corporation , a biophama company developing small-molecule and protein therapeutics for inflammatory diseases and bleeding and nervous disorders, saw its shares climb by as much as 85% today on tremendous volume. This huge...
OMER: 16.25 (-0.32)
Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
PR Newswire - Tue Aug 18, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) - aggregations of platelets - in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of TMAs, including atypical hemolytic uremic syndrome (aHUS).
OMER: 16.25 (-0.32)
Omeros Announces Plan to File Infringement Suit Against ANDA Filer
PR Newswire - Mon Aug 17, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (Par) in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria® (phenylephrine and ketorolac injection) 1%/0.3%. Omidria is approved by the U.S. Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. As reported in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2015, Omeros received a notice from Par on July 27, 2015, which addresses the ANDA and Par's request to market a generic version of Omidria pursuant to Paragraph IV of the Hatch-Waxman Act following expiration of the drug's New Product Exclusivity and, if applicable, the subsequent Pediatric Exclusivity, but prior to the expiration of three patents published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, which have terms extending to as late as 2033. Approximately 3.8 million cataract and lens replacement procedures are projected in the U.S. in 2015.
OMER: 16.25 (-0.32)
Melanoma - Pipeline Review, H1 2015
M2 - Fri Aug 14, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sfh3j3/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Partial list of the 200 companied featured in this comprehensive report: - Aeterna Zentaris - Altor BioScience - Bayer AG - Bio-Cancer Treatment International - Boston Biomedical - Celgene Corporation - Champions Oncology - DNA Therapeutics - DormaTarg - EcoBiotics - Eli Lilly and Company - F. Hoffmann-La Roche - Galapagos - Hadasit Medical Research Services & Development - KAEL-GemVax - Life Science Pharmaceuticals - MedImmune - Merck & Co. - Millennium Pharmaceuticals - Navigen Pharmaceuticals - Nektar Therapeutics - Omeros Corporation - Pacific Northwest Biotechnology - Pfizer - Pivotal BioSciences - Qu Biologics - Reata Pharmaceuticals - Scancell - Takeda Pharmaceutical Company - Ultimovacs - Vaccibody - Viralytics - Welichem Biotech - ZIOPHARM Oncology For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/sfh3j3/melanoma
ZIOP: 8.40 (+0.37), MRK: 54.42 (+3.25), LLY: 81.10 (+2.84), NKTR: 10.08 (+0.25), OMER: 16.25 (-0.32), CELGZ: 1.68 (+0.12)
BUYINS.NET: SHOR, HAP, DZK, OMER, SCHC, NXPI Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Aug 12, 6:59AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Shoretel Inc (NASDAQ:SHOR), Market Vectors RVE Hard Assets Producers ETF (NYSE:HAP), Direxion Daily Developed Markets Bull 3X Shares (NYSE
ZK), Omeros Corp (NASDAQ:OMER), Schwab US Large Cap Etf (NYSE:SCHC), NXP Semiconductors NV (NASDAQ:NXPI) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: DZK: 53.32 (+3.45), SCHC: 28.93 (+0.74), NXPI: 85.02 (+4.18), HAP: 27.79 (+0.25), OMER: 16.25 (-0.32), SHOR: 7.41 (+0.40)
Omeros reports 2Q loss
Automated Insights - Mon Aug 10, 5:33PM CDT
SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $16.7 million in its second quarter.
OMER: 16.25 (-0.32)
Omeros Corporation Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 10, 3:11PM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the second quarter of 2015, which include:
OMER: 16.25 (-0.32)
Omeros to Present at the 2015 Wedbush PacGrow Healthcare Conference
PR Newswire - Fri Aug 07, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2015 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, August 11 at 12:45 pm EDT.
OMER: 16.25 (-0.32)
Omidria® Approved for Commercialization Throughout the European Union and Additional Countries
PR Newswire - Mon Aug 03, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. This approval allows for the marketing of Omidria in all EU member states plus Iceland, Lichtenstein, and Norway. Cataract surgery and lens replacement are among the most common surgical procedures worldwide, with approximately 3.9 million of them expected to be performed in Western Europe alone in 2015.
OMER: 16.25 (-0.32)
Omeros Corporation to Announce Second Quarter 2015 Financial Results on August 10, 2015
PR Newswire - Fri Jul 31, 3:50PM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its second quarter 2015 financial results for the period ended June 30, 2015, on Monday, August 10, 2015, after market close. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.
OMER: 16.25 (-0.32)
Ischemia Reperfusion Injury Pipeline Review, H1 2015 - 24 Companies & 63 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mw2sb6/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adienne Pharma & Biotech - Alligator Bioscience AB - Antipodean Pharmaceuticals, Inc. - BioLineRx, Ltd. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Catalyst Biosciences, Inc. - Curatis Pharma GmbH - Gilead Sciences, Inc. - Ischemix - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Mercury Pharmaceuticals, Inc. - Omeros Corporation - Opsona Therapeutics Ltd. - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. - Prothix BV - Trophos SA - Zealand Pharma A/S - Zyrnat Biotherapeutics SL Drug Profiles - ADC-1004 - AM/AMBP-1 - ANV-6L15 - APP-103 - BBT-030 - BBT-045 - BL-7060 - C1 esterase inhibitor (recombinant) - CB-2782 - CMX-2043 - CRX-526 - Curaglutide - danegaptide - Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Elafin - EP-80317 - Ergidina - GS-459679 - KN-93 - KR-62980 - LSNTU-106 - mangafodipir - MFH-244 - MG-53 - mirococept - MitoQ - Monoclonal Antibody for Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - MTP-131 - NBD Peptide - NecX - Neutrolide - NOXD-21 For more information visit http://www.researchandmarkets.com/research/mw2sb6/ischemia
GILD: 106.96 (+4.40), OMER: 16.25 (-0.32)
